Clinical Trials Browser

OTHER × tislelizumab × Genitourinary × Clear all

NCT07296705 2025-12-22

HARBOR

Phase 2 Recruiting

Muscle Invasive Bladder Cancer (MIBC)

NCT05189457 2025-12-04

First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT06866548 2025-12-04

Safety and Efficacy Evaluation of Anti IGF-1R Monoclonal Antibody Combined With Anti-PD-1 Monoclonal Antibody in Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

Phase EARLY_PHASE1 Active not recruiting

Insulin-Like Growth Factor I, Resistance To, Neoplasm Metastasis, Prostatic Neoplasms

NCT07233252 2025-11-18

Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic Cancer

Phase 2 Recruiting

Renal Pelvic Carcinoma

NCT07119996 2025-08-13

Clinical Trial on the Protective Role of Vitamin B3 in Enhancing Immunotherapy for Bladder Cancer Patients

Phase 1 Not yet recruiting

Urinary Bladder Neoplasms, Neoplasms

NCT06916494 2025-04-10

Pilot Study on Rutin Combined With Tislelizumab and GC (Gemcitabine and Cisplatin) as Neoadjuvant Therapy for Platinum-refractory Muscle-invasive Bladder Cancer

Phase 1 Recruiting

Muscle Invasive Bladder Cancer

NCT04802876 2025-03-21

ACROPOLI

Phase 2 Active not recruiting

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmSarcomaThoracic

Adenocarcinoma Of Esophagus, Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Uveal Melanoma, Anus Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Neoplasms, Unknown Primary, Sarcoma, Thyroid Neoplasms, Cholangiocarcinoma, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT06364904 2025-02-21

A Clinical Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma.

Phase 3 Not yet recruiting

Urinary Bladder Neoplasms

NCT06630871 2024-10-10

A Clinical Trial Evaluating the Efficacy and Safety of Disitamab Vedotin Plus Tislelizumab Combined with Re-TURBT in the Treatment of HER-2-high Expression(2+-3+) Non-muscle Invasive Bladder Cancer At High-risk and Very High-risk.

Phase 2 Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT05531123 2024-07-12

Risk-stratification Based Bladder-sparing Modalities for Muscle-invasive Bladder Cancer

Phase 2 Recruiting

Urinary Bladder Neoplasms

NCT06441110 2024-06-04

Multicenter Clinical Trial on the Effectiveness and Safety of Instillation of BCG and Alternative BCG Protocols for Intermediate and High-risk Non-muscle Invasive Bladder Cancer

Phase 3 Recruiting

Urinary Bladder Neoplasms, Motor Activity, Neoplasm Recurrence, Local

NCT06387056 2024-04-26

SEGNO

Phase 2 Recruiting

Locally Advanced Prostate Cancer

NCT06211790 2024-01-18

Proteomic Guided First-line Precision Treatment of Renal Clear Cell Carcinoma

Phase 2 Recruiting

Carcinoma, Renal Cell, Kidney Neoplasms

NCT05957757 2023-08-31

RC48 Combined With Tislelizumab for Bladder Sparing Treatment in NMIBC With BCG Treatment Failure and HER2 Expression

Phase 2 Recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT05445648 2022-12-28

CBPTMI

Phase 2 Unknown

Urinary Bladder Neoplasms

NCT04730219 2022-11-30

Perioperative Tislelizumab Combined With Nab-Paclitaxel for Muscle-invasive Urothelial Bladder Carcinoma

Phase 2 Unknown

Carcinoma, Transitional Cell

NCT05580354 2022-10-14

Safety and Efficacy of BCG Combined With Tislelizumab for BCG-untreated Patients With High-risk Non-muscle Invasive Bladder Cancer

Phase 4 Unknown

Non-Muscle Invasive Bladder Neoplasms

NCT05401279 2022-08-18

Bladder Sparing Treatment of Tislelizumab, Gemcitabine and Cisplatin for Patients With PD-L1 Positive Muscle Invasive Bladder Cancer

Phase 2 Unknown

Urothelial Carcinoma Bladder

NCT04922047 2021-06-11

TACBIN-01

Phase 1/2 Unknown

Urinary Bladder Diseases, Urinary Bladder Neoplasms, Urogenital Neoplasms, Urologic Neoplasms